Genco Lab was accused of billing Medicaid and Medicare programs for unnecessary screening and confirmatory tests for the use of prohibited drugs.

The new ruling reverses a jury verdict from four years ago that handed ArcherDx, which no longer exists, $4.7 million in damages.

The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple entities as well as other in vitro diagnostic tests.

TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage test.

The firm said that it will use the money for working capital and general corporate purposes, and the raise follows a $3.25 million public offering that closed in May.

ArteraAI Prostate is authorized for use as a tool to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.

NEW YORK – The World Health Organization on Monday released an update to its operational handbook on the diagnosis of tuberculosis that provides laboratory personnel, clinicians, ministries of health, ...

Last week, readers were most interested in a story about Diasorin's preparation to enter the point-of-care molecular testing space with a benchtop instrument.

The target device includes a portable instrument and 30-minute, $5 assays requiring only small volumes of whole capillary blood.

NEW YORK – Tempus AI on Friday morning announced that its Q2 2025 revenues rose 90 percent year over year, driven by strong diagnostics sales. Tempus reported revenues of $314.6 million for the ...